PE20090241A1 - Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 - Google Patents

Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12

Info

Publication number
PE20090241A1
PE20090241A1 PE2008000685A PE2008000685A PE20090241A1 PE 20090241 A1 PE20090241 A1 PE 20090241A1 PE 2008000685 A PE2008000685 A PE 2008000685A PE 2008000685 A PE2008000685 A PE 2008000685A PE 20090241 A1 PE20090241 A1 PE 20090241A1
Authority
PE
Peru
Prior art keywords
alkyl
quinoline
alkenyl
covalent link
heterocyclyl
Prior art date
Application number
PE2008000685A
Other languages
English (en)
Spanish (es)
Inventor
Joerg Czech
Gerhard Hessler
Melitta Just
Marc Nazare
Tilo Weiss
Gernot Zech
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20090241A1 publication Critical patent/PE20090241A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2008000685A 2007-04-23 2008-04-21 Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 PE20090241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07008209 2007-04-23

Publications (1)

Publication Number Publication Date
PE20090241A1 true PE20090241A1 (es) 2009-04-03

Family

ID=38462433

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000685A PE20090241A1 (es) 2007-04-23 2008-04-21 Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12

Country Status (18)

Country Link
US (1) US8669266B2 (enExample)
EP (1) EP2148871A1 (enExample)
JP (1) JP5309131B2 (enExample)
KR (1) KR20100015886A (enExample)
CN (1) CN101663293B (enExample)
AR (1) AR066225A1 (enExample)
AU (1) AU2008241091B2 (enExample)
BR (1) BRPI0810462A2 (enExample)
CA (1) CA2684644A1 (enExample)
CL (1) CL2008001157A1 (enExample)
IL (1) IL201620A (enExample)
MX (1) MX2009011089A (enExample)
MY (1) MY153427A (enExample)
PA (1) PA8777901A1 (enExample)
PE (1) PE20090241A1 (enExample)
TW (1) TW200848042A (enExample)
UY (1) UY31039A1 (enExample)
WO (1) WO2008128647A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235694B2 (en) 2001-02-28 2007-06-14 Covalon Technologies Inc. Method of making anti-microbial polymeric surfaces
WO2009082526A2 (en) * 2007-10-05 2009-07-02 Pharmacopeia, Inc. Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
TWI361690B (en) 2007-11-29 2012-04-11 Actelion Pharmaceuticals Ltd Phosphonic acid derivatives
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
WO2010116328A2 (en) * 2009-04-08 2010-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 3−(ビアリールオキシ)プロピオン酸誘導体
AR079451A1 (es) * 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
CN103857288B (zh) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的氨基-喹啉
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
EP2725025A1 (fr) * 2012-10-26 2014-04-30 Sanofi Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12
EP2958911B1 (en) 2013-02-21 2017-10-18 GlaxoSmithKline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
DE102015217396B4 (de) 2014-09-11 2018-07-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
KR102510832B1 (ko) 2017-03-15 2023-03-15 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여
CN107648607A (zh) * 2017-09-11 2018-02-02 南昌大学 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023108363A1 (en) * 2021-12-13 2023-06-22 Beijing Honghui Meditech Co., Ltd Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition
CN115429874A (zh) * 2022-09-20 2022-12-06 暨南大学 水蛭素靶向并抑制dpp4治疗糖尿病

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
KR20050085580A (ko) * 2002-12-11 2005-08-29 쉐링 악티엔게젤샤프트 혈소판 아데노신 디포스페이트 수용체 길항제로서의2-아미노카르보닐-퀴놀린 화합물
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
US7157445B2 (en) * 2004-02-26 2007-01-02 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.

Also Published As

Publication number Publication date
WO2008128647A1 (en) 2008-10-30
AU2008241091B2 (en) 2013-05-09
JP5309131B2 (ja) 2013-10-09
CN101663293B (zh) 2013-07-31
US8669266B2 (en) 2014-03-11
KR20100015886A (ko) 2010-02-12
HK1141803A1 (en) 2010-11-19
PA8777901A1 (es) 2008-11-19
CN101663293A (zh) 2010-03-03
MY153427A (en) 2015-02-13
IL201620A (en) 2013-11-28
CA2684644A1 (en) 2008-10-30
CL2008001157A1 (es) 2008-11-03
JP2010524984A (ja) 2010-07-22
BRPI0810462A2 (pt) 2014-10-14
MX2009011089A (es) 2009-10-30
AU2008241091A1 (en) 2008-10-30
EP2148871A1 (en) 2010-02-03
UY31039A1 (es) 2008-11-28
TW200848042A (en) 2008-12-16
AR066225A1 (es) 2009-08-05
US20100135999A1 (en) 2010-06-03
IL201620A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
PE20090241A1 (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20070848A1 (es) Derivados de pirimidina como ligandos del receptor de histamina h4
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20110924A1 (es) Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20080211A1 (es) Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal